Tri Burgdorferi: borrelia-bakteeri/selittämättömät oireet

Valvojat: Borrelioosiyhdistys, Bb, Jatta1001

Vastaa Viestiin
soijuv
Viestit: 3151
Liittynyt: Ke Tammi 21, 2009 14:16

Tri Burgdorferi: borrelia-bakteeri/selittämättömät oireet

Viesti Kirjoittaja soijuv » To Marras 24, 2011 17:06

http://www.topsecretwriters.com/2011/11 ... -pandemic/

Borrelia-bakteeri saattaa aiheuttaa pandemian. Borrelia-bakteerin löytäjän tri W.Burgdorferin mukaan kannattaa selvittää borrelia-bakteerin osuus omiin selittämättömiin, monimuotoisiin oireisiin.

Lyme Disease May Represent a Troubling Human Pandemic

Earlier this month, we took a closer look at the origins of Lyme disease and the evidence linking its possible connections to the Plum Island Animal Disease Center.

Without a full-scale investigation by the Justice Department, or a voluntary admission from the government that they accidentally released the bacteria that started Lyme disease in 1975, the world may unfortunately never know what really happened.

However, what science does offer is a trail of evidence that allows researchers to not only define the nature of the disease itself, but it allows biologists the ability to analyze and reverse engineer the bacteria in order to understand its true nature.

In fact, according to a non-publicized study conducted in 2003 by Diversified Medical Practices in Houston, Texas, you may very well need to throw everything that you think you know about Lyme disease out the window.
Testing Chronically Ill Patients

In 2003, W. T. Harvey and P. Salvato published the results of a study into a comparison of existing literature regarding Lyme disease with their own observations of their patients allegedly suffering from what is classified as ?Lyme disease? by the CDC.

What concerned the two physicians was the fact that their testing of patients for Borrelia burgdorferi (Bb) infection aroused suspicion that the bacteria may be responsible for far more than just the standard symptoms associated with what is commonly called Lyme disease.

The physicians tested all of their chronically-ill patients for Borrelia burgdorferi, regardless of any presence of a rash, and found that a third of the initial tests were positive. This shocked the doctors, because in most medical clinics, since the patients did not present the classic ?symptoms? of Lyme Disease, they never would be tested for Bb infection.

It especially disturbed the physicians because the prevalence of Borrelia infected ticks in Texas is only about 1 to 2% ? so the next question is how so many of these Texas patients became infected.

With this evidence in hand, the physicians set out on a mission to explore the existing case studies on Bb infection to determine whether or not they might have discovered a disturbing situation where Borrelia burgdorfer infection among the human population is far worse than anyone suspects.
Uncovering Medical Myths about Lyme Disease

What the doctors discovered was a disturbing trend where existing research into Borrelia burgdorferi infection focuses primarily on humans portraying symptoms that match the modern medical definition of ?Lyme Disease?.

For example, the assumption that a rash will be present alongside Lyme Disease may not always be true. According to the research, the doctors discovered that rash does not always exist alongside Bb infection.

?This assumption [that a rash is present] is, in fact, the foundation of many important conclusions reached about ?Lyme disease? despite numerous papers that acknowledge secondary EM lesions occur (15,17). Available data do not support the EM rash to be dependable for diagnosis. The EM rash may follow initial tick inoculation (primary), or it may occur months to years later (secondary) (19?28). The rash also frequently fails to appear following tick inoculation (26).?

This means that the lack of a rash is not a sure-fire sign that there is no Borrelia burgdorferi infection. The doctors go on to explain that in many cases, the infections can actually go completely unnoticed in some individuals, at least at first.

?Copious data support that B. burgdorferi infection can be ?sub-clinical? and thus unnoticed in infected individuals (20,30?54) and animals (55,56).?

The doctors then further hypothesis in their paper that it might be possible the infection does not actually produce any symptoms on some humans, until months or even years down the road when the symptoms of Bb infection start to show up in the form of Chronic illnesses that many doctors can?t nail down to any particular cause such as chronic pain, chronic fatigue and similar symptoms.

?The question of whether sub-clinical cases activate or fail to activate at some future date is intriguing.?

This observation is the first sign that medical science may not know even a fraction of what it claims to know about Lyme Disease.
The Ability of Borrelia Burgdorferi to Live for Prolonged Periods in the Body

One of the most disturbing initial findings about Lyme disease was actually made by Dr. ?Willy? Burgdorfer, who first discovered the bacteria in the form of the odd ?spirochete? in 1982.

Burgdorfer and other scientists realized that the spirochete had the unique ability ? unlike other bacteria ? to infiltrate through certain tissue without actually causing a typical immune-response.

The Texas researchers point to this fact to bolster the idea that Bb could live in the body for an extended period without provoking an immune response.

?Pleomorphism, variable antigen presentation, immune avoidance, individual immune variance, host-derived enzyme cloaking, immune complex sequestration, and antibody inaccessibility to spirochete-privileged sites argue against sustained or consistent immune response (88?92).?

The doctors next blow the idea out of the water that only ticks can be carriers of the infectious agent.

?Data are available, however, that expand the possible diversity of Borrelia vectors worldwide beyond the arthropod. Other possible carriers include the flea (108,109), mosquito (110?112), fly (111), and mite (113). Related enzootic cycles have been only rarely examined, although some data link non-arthropod vectors with animal hosts (110,112?114).?

And in the most shocking claim of the report, the doctors suggest that even humans may be able to serve as infectious carriers of Bb, and may be able to pass along the silent agent to fellow humans.

?CDC-defining criteria do not address human congenital transfer and in at least one reference deny without proof that sexual transfer occurs (17). This mindset assures that Bbsl cases falling outside ?Lyme disease? criteria have not been considered in most research, nor reported to local health agencies.?

The researchers continue:

?Our clinical experience strongly suggests that predictable, possibly inevitable Bbsl transfer between sexually active couples occurs. The preponderance of infected spouses we have tested to date also exhibit positive serology or PCR for Bbsl presence.?

Signs of a Silent Global Pandemic

The researchers in the study, after realizing that the CDC has very likely failed to properly characterize the scope of the global infection rates for the Bb agent, propose that the disease should be reclassified and treated as a global pandemic.

?We propose there are at least two similar and unified, but distinct forms of human B. burgdorferi infection: ?Lyme disease?, and ?Epidemic Borreliosis? (disease spread directly between humans). Late (more than one year old) zoonotic disease may overlap both forms.

We propose that ?Lyme disease? is a limited conceptualization of a far more pervasive Borrelia infection state that is now an unrecognized global epidemic.?

Confirmation from Dr. Burgdorfer

In 2007, UnderOurSkin.com set up an interview with Dr. Burgdorfer to discuss Lyme Disease and his impressive research in the field. According to the interviewers, they were visited by a researcher from Rocky Mountain Laboratories.

?Just as we began filming, there was a pounding on the door, and we found ourselves facing someone who turned out to be a top researcher at the nearby Rocky Mountain Laboratories, a biolevel-4 NIH research facility. Standing on the porch, our uninvited guest said, ?I?ve been told that I need to supervise this interview. This comes from the highest levels. There are things that Willy can?t talk about.??

The incident was especially odd, because Dr. Burgdorfer had retired back in 1986. However, the interview continued, and the following statement from Dr. Burgdorfer during the interview is especially shocking in light of the 2003 study.

?You cannot find this spirochete. Why not? After all, I have a sick person here. He is trembling all over. His synovial fluid is full of spirochetes. But when it comes to blood, it?s not there. So there is something associated with this organism that makes it different.?

Finally, Burgdorfer continues with the kicker:

?I am a believer in persistent infections because people suffering with Lyme disease, ten or fifteen or twenty years later, get sick [again]. Because it appears that this organism has the ability to be sequestered in tissues and [it] is possible that it could reappear, bringing back the clinical manifestations it caused in the first place. These are controversial issues for microbiologists, as well as the physicians who are asked to treat patients.?

And finally, Dr. Burgdorferi confirms the conclusions of the Texas study that the Bb agent is far more serious an infectious agent than the current medical field is telling patients.

?I think Borrelia burgdorferi is too serious an [infectious] agent to play with, and with many laboratories, the severity of the disease is overlooked.?

In other words, Dr. Burgdorferi?s statements support the epidemic theory. If you suffer from chronic symptoms, have explored all possibilities and feel like you?re out of options ? it could be worthwhile to request a Borrelia burgdorferi infection test (CDC Western blot criteria or serum/urine PCR).

Being a part of the Bb epidemic is not an appealing thought, but at least you will know what you?re dealing with.


?> http://www.ilads.org/files/harvey.pdf
?> Interview with Burgdorfer

Image Credit:
?> GeorgiaLymeDisease.org
?> NIH.gov

soijuv
Viestit: 3151
Liittynyt: Ke Tammi 21, 2009 14:16

Borrelioosin diagnostiikka 2011

Viesti Kirjoittaja soijuv » To Marras 24, 2011 17:10

The 2011 Lyme Disease Diagnostics Market: US, Europe, Japan
Test Volume, Sales Forecasts and Supplier Shares by Country
Share
By Reportlinker
Published: Wednesday, Nov. 16, 2011 - 8:19 am

NEW YORK, Nov. 16, 2011 -- /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics title='The 2011 Lyme Disease Diagnostics Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Lyme Disease Diagnostics Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

http://www.reportlinker.com/p0444720/Th ... rope-Japan

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments:

- Hospitals

- Commercial/Private Labs

-Physician Offices

- Public Health Labs

In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Lyme disease tests.

Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Contains 203 pages and 11 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

A. Background

Clinical Description

Clinical Case Definition

Laboratory Criteria for Diagnosis

Case Classification

B. Diagnostic Tests

C. Vaccines and Drugs

D. Emerging Diagnostic Technologies

1. DNA Probes

a. Technology Overview

b. Amplification Methods

Polymerase Chain Reaction

Robotics

Temperature Cyclers

PCR Variations

Immuno-PCR

QC-PCR

DAP-PCR

Ligase Chain Reaction

Branched DNA

Q-Beta Replicase

Nucleic-Acid Sequence-Based

Strand Displacement Activation

Self-Sustained Sequence Replicase

2. Monoclonal Antibodies

3. Immunoassays

a. Technological Principle

b. Enzyme Immunoassays (EIA)

Overview

ELISA

Dot Immunobinding Assays

Capillary Immunoassays

Particle-Membrane Capture Immunoassays

Enzyme Amplification

c. Fluorescent Immunoassays

Fluorescence Polarization

Time-Resolved Pulse Fluorescence

d. Luminescence

Chemiluminescence

Bioluminescence

e. Latex Agglutination

f. Immunoprecipitation

4. Differential Light Scattering

5. Microcomputers and Automation

6. Artificial Intelligence

7. Liposomes

8. Flow Cytometry

9. Chromatography

10. MRI

11. Gel Microdroplets

12. Other

III. France: Market Size, Growth and Major Suppliers' Sales and Market Shares

IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment

V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment

VI. Japan: Test Volume and Diagnostics Sales Forecast by Market Segment

VII. Spain: Market Size, Growth and Major Suppliers' Sales and Market Shares

VIII. UK: Test Volume and Diagnostics Sales Forecast by Market Segment

IX. USA: Market Size, Growth and Major Suppliers' Sales and Market Shares

X. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

XI. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XII. Competitive Assessments

Abbott

Affymetrix

Applera

Beckman Coulter

Becton Dickinson

Binding Site

Biomerica

Biokit

bioMerieux

Bio-Rad

Biotrol

Biosite

Biotest

Caliper Technologies

Cepheid

Chemicon

Daiichi

DiaSorin

Diagast

Diamedix

Digene

Eiken

Enzo Biochem

Fujirebio

GenBio

Gene-Tec

Hemagen

Immunetics

Innogenetics

Inverness

J&J

Meridian

Nanogen

Nissui

Olympus

Provalis

Roche

Saliva Diagnostic

SeraCare

Siemens

Third Wave Technologies

Thermo Fisher

Tosho

Trinity Biotech

Tropix

Wampole Labs

Zenith

Zeus

List of Tables

Major Companies Developing or Marketing Lyme Disease Tests

France

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

France

Lyme Disease Testing Market Diagnostics Sales by Major Supplier

Germany

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

Italy

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

Japan

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

Spain

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

Spain

Lyme Disease Testing Market Diagnostics Sales by Major Supplier

U.K.

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

Lyme Disease Testing Market Diagnostics Sales by Major Supplier

To order this report:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics title='The 2011 Lyme Disease Diagnostics Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Lyme Disease Diagnostics Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

More Market Research Report

Check our Real Time Industry Data

CONTACT: Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Vastaa Viestiin